{"filing":{"accession_number":"0001213900-26-111026","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-14","primary_document":"ea0309080-8k_tempest.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000121390026111026/ea0309080-8k_tempest.htm"},"events":[{"id":36403,"run_id":33568,"accession_number":"0001213900-26-111026","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Tempest Therapeutics held a special stockholder meeting on October 14, 2026, to vote on a Certificate of Amendment proposal to replace supermajority voting requirements and permit written consent. The proposal failed to achieve the required 75% affirmative vote, and the meeting was adjourned to reconvene on November 12, 2026, with 11,004,101 shares (74.3% of outstanding) present at the initial meeting.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40811,"accession_number":"0001213900-26-111026","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 5.07 is the dedicated 8-K Item for shareholder vote results at annual or special meetings. The filing incorporates Item 8.01 by reference, which typically contains the substantive details of the vote outcomes. While the specific vote results are not detailed in this excerpt, the Item 5.07 designation and cross-reference to Item 8.01 indicate shareholder voting matters were submitted and decided.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:09:52.532573+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40812,"accession_number":"0001213900-26-111026","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the results of a special stockholder meeting held on October 14, 2026, where a Certificate of Amendment proposal to replace supermajority voting requirements and permit written consent failed to achieve the required 75% affirmative vote. Although the meeting was adjourned to reconvene on November 12, 2026, the disclosure of the voting outcome (insufficient votes at the time of the meeting) and the quorum information (11,004,101 shares or 74.3% present) constitutes a shareholder vote result under Item 5.07 principles, even though technically classified under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:09:52.532573+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40811,"accession_number":"0001213900-26-111026","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 5.07 is the dedicated 8-K Item for shareholder vote results at annual or special meetings. The filing incorporates Item 8.01 by reference, which typically contains the substantive details of the vote outcomes. While the specific vote results are not detailed in this excerpt, the Item 5.07 designation and cross-reference to Item 8.01 indicate shareholder voting matters were submitted and decided.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:09:52.532573+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-20"},{"id":40812,"accession_number":"0001213900-26-111026","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the results of a special stockholder meeting held on October 14, 2026, where a Certificate of Amendment proposal to replace supermajority voting requirements and permit written consent failed to achieve the required 75% affirmative vote. Although the meeting was adjourned to reconvene on November 12, 2026, the disclosure of the voting outcome (insufficient votes at the time of the meeting) and the quorum information (11,004,101 shares or 74.3% present) constitutes a shareholder vote result under Item 5.07 principles, even though technically classified under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T20:09:52.532573+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-20"}]}